AUA 2017: Institutional Learning Curve Associated with Implementation of a MRI/US Fusion Biopsy Program Using Pirads Vesion 2: Factors that Influence Success
Boston, MA (UroToday.com) Dr. Truong presented on the topic of an institutional learning curve for a MRI/ultrasound (US) fusion biopsy program and factors that influence success. Their objective was to identify if a learning curve exists for MRI/US fusion biopsies. Using readily available data from a few clinical centers, Dr. Truong and colleagues looked to identify patient and technical factors which influenced the success of the detection of clinically significant prostate cancer (defined as Gleason score ≥3+4). They found that the most important factor was the interpretation by experienced radiologists. Cancer detection of clinically significant prostate cancer was 6% for PIRADS 3, 46% for PIRADS 4, and 66% for PIRADS 5 lesions with an area under the curve of 0.79. In addition they found the use of 4 biopsies for each target helped to maximize sampling of the targeted areas and confirm Gleason score ≥3+4.
MR/US fusion biopsies are being rapidly adopted in many clinical centers, and thus, this study provides valuable information. Using previously published literature of detection rates is important in the benchmarking and to assess adequate adoption of the new technology. Establishing quality control is important when integrating new technology into clinical practice.
Presented by Matt Truong, MD from the University of Rochester, Rochester, NY
Written By: Janet Baack Kukreja (@janetkukreja), MD, MPH, Urologic Oncology Fellow, Department of Urology, UT MD Anderson Cancer Center, Houston, TX, Ashish M. Kamat, MD, MBBS, FACS, Wayne B. Duddlesten Professor, Department of Urology, UT MD Anderson Cancer Center, Houston TX
at the 2017 AUA Annual Meeting - May 12 - 16, 2017 – Boston, Massachusetts, USA